Bone mineral content in patients with calcium urolithiasis

Segun Lawoyin, Scott Sismilich, Richard Browne, Charles Y C Pak

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

125I-photon absorptiometry was used to determine bone density (bone mineral content/bone width) in the distal third of the radius in 117 patients with absorptive hypercalciuria, 44 with renal hypercalciuria, 53 with primary hyperparathyroidism, and 69 patients with osteoporosis. Observed bone density in each patient was compared to the mean bone density for age- and sex-matched control subjects; the magnitude of the fractional change from control mean bone density was determined for each of the groups listed. In absorptive hypercalciuria, with normal or suppressed parathyroid function, the mean fractional change in bone density of -0.0010 was virtually identical to and not significantly different from the control mean (or zero). In renal hypercalciuria with secondary hyperparathyroidism, the mean fractional change in bone density of -0.0746 was significantly lower than the control mean (p < 0.001 by one-sample t-test; 95% confidence interval on mean fractional change ranges from -0.0970 to -0.0530). Similarly, the fractional change in bone density was significantly reduced (p < 0.001) in primary hyperparathyroidism and in osteoporosis (mean changes of -0.1275 and -0.1516, respectively). Individual value for bone density was below the lower limit of the 95% prediction interval for observations from control subjects in only one of 117 patients with absorptive hypercalciuria; it was low in 5 of 44 patients with renal hypercalciuria. These findings provide an additional support for the validity of separation of absorptive hypercalciuria from renal hypercalciuria.

Original languageEnglish (US)
Pages (from-to)1250-1254
Number of pages5
JournalMetabolism
Volume28
Issue number12
DOIs
StatePublished - 1979

Fingerprint

Urolithiasis
Hypercalciuria
Bone Density
Calcium
Kidney
Primary Hyperparathyroidism
Osteoporosis
Bone and Bones
Secondary Hyperparathyroidism
Photon Absorptiometry
Confidence Intervals

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Bone mineral content in patients with calcium urolithiasis. / Lawoyin, Segun; Sismilich, Scott; Browne, Richard; Pak, Charles Y C.

In: Metabolism, Vol. 28, No. 12, 1979, p. 1250-1254.

Research output: Contribution to journalArticle

Lawoyin, Segun ; Sismilich, Scott ; Browne, Richard ; Pak, Charles Y C. / Bone mineral content in patients with calcium urolithiasis. In: Metabolism. 1979 ; Vol. 28, No. 12. pp. 1250-1254.
@article{a7060607de534a31a9cfcfb63660bb25,
title = "Bone mineral content in patients with calcium urolithiasis",
abstract = "125I-photon absorptiometry was used to determine bone density (bone mineral content/bone width) in the distal third of the radius in 117 patients with absorptive hypercalciuria, 44 with renal hypercalciuria, 53 with primary hyperparathyroidism, and 69 patients with osteoporosis. Observed bone density in each patient was compared to the mean bone density for age- and sex-matched control subjects; the magnitude of the fractional change from control mean bone density was determined for each of the groups listed. In absorptive hypercalciuria, with normal or suppressed parathyroid function, the mean fractional change in bone density of -0.0010 was virtually identical to and not significantly different from the control mean (or zero). In renal hypercalciuria with secondary hyperparathyroidism, the mean fractional change in bone density of -0.0746 was significantly lower than the control mean (p < 0.001 by one-sample t-test; 95{\%} confidence interval on mean fractional change ranges from -0.0970 to -0.0530). Similarly, the fractional change in bone density was significantly reduced (p < 0.001) in primary hyperparathyroidism and in osteoporosis (mean changes of -0.1275 and -0.1516, respectively). Individual value for bone density was below the lower limit of the 95{\%} prediction interval for observations from control subjects in only one of 117 patients with absorptive hypercalciuria; it was low in 5 of 44 patients with renal hypercalciuria. These findings provide an additional support for the validity of separation of absorptive hypercalciuria from renal hypercalciuria.",
author = "Segun Lawoyin and Scott Sismilich and Richard Browne and Pak, {Charles Y C}",
year = "1979",
doi = "10.1016/0026-0495(79)90139-2",
language = "English (US)",
volume = "28",
pages = "1250--1254",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Bone mineral content in patients with calcium urolithiasis

AU - Lawoyin, Segun

AU - Sismilich, Scott

AU - Browne, Richard

AU - Pak, Charles Y C

PY - 1979

Y1 - 1979

N2 - 125I-photon absorptiometry was used to determine bone density (bone mineral content/bone width) in the distal third of the radius in 117 patients with absorptive hypercalciuria, 44 with renal hypercalciuria, 53 with primary hyperparathyroidism, and 69 patients with osteoporosis. Observed bone density in each patient was compared to the mean bone density for age- and sex-matched control subjects; the magnitude of the fractional change from control mean bone density was determined for each of the groups listed. In absorptive hypercalciuria, with normal or suppressed parathyroid function, the mean fractional change in bone density of -0.0010 was virtually identical to and not significantly different from the control mean (or zero). In renal hypercalciuria with secondary hyperparathyroidism, the mean fractional change in bone density of -0.0746 was significantly lower than the control mean (p < 0.001 by one-sample t-test; 95% confidence interval on mean fractional change ranges from -0.0970 to -0.0530). Similarly, the fractional change in bone density was significantly reduced (p < 0.001) in primary hyperparathyroidism and in osteoporosis (mean changes of -0.1275 and -0.1516, respectively). Individual value for bone density was below the lower limit of the 95% prediction interval for observations from control subjects in only one of 117 patients with absorptive hypercalciuria; it was low in 5 of 44 patients with renal hypercalciuria. These findings provide an additional support for the validity of separation of absorptive hypercalciuria from renal hypercalciuria.

AB - 125I-photon absorptiometry was used to determine bone density (bone mineral content/bone width) in the distal third of the radius in 117 patients with absorptive hypercalciuria, 44 with renal hypercalciuria, 53 with primary hyperparathyroidism, and 69 patients with osteoporosis. Observed bone density in each patient was compared to the mean bone density for age- and sex-matched control subjects; the magnitude of the fractional change from control mean bone density was determined for each of the groups listed. In absorptive hypercalciuria, with normal or suppressed parathyroid function, the mean fractional change in bone density of -0.0010 was virtually identical to and not significantly different from the control mean (or zero). In renal hypercalciuria with secondary hyperparathyroidism, the mean fractional change in bone density of -0.0746 was significantly lower than the control mean (p < 0.001 by one-sample t-test; 95% confidence interval on mean fractional change ranges from -0.0970 to -0.0530). Similarly, the fractional change in bone density was significantly reduced (p < 0.001) in primary hyperparathyroidism and in osteoporosis (mean changes of -0.1275 and -0.1516, respectively). Individual value for bone density was below the lower limit of the 95% prediction interval for observations from control subjects in only one of 117 patients with absorptive hypercalciuria; it was low in 5 of 44 patients with renal hypercalciuria. These findings provide an additional support for the validity of separation of absorptive hypercalciuria from renal hypercalciuria.

UR - http://www.scopus.com/inward/record.url?scp=0018641640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018641640&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(79)90139-2

DO - 10.1016/0026-0495(79)90139-2

M3 - Article

C2 - 514087

AN - SCOPUS:0018641640

VL - 28

SP - 1250

EP - 1254

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 12

ER -